Miconazole nitrate cream and preparation process thereof

By optimizing the preparation process of miconazole nitrate and adding allantoin eugenol amide ester penetration promoter, nano-scale miconazole nitrate cream was prepared, which solved the problems of long treatment cycles, short drug releases and insufficient skin penetration in the prior art, and achieved more efficient fungal infection treatment and cream stability.

CN120131535AActive Publication Date: 2025-06-13GUANGZHOU BAICAOTANG PHARMA
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202510285228.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-03-11
Publication Date
2025-06-13
Estimated Expiration
2045-03-11

AI Technical Summary

Technical Problem

The existing miconazole nitrate cream has a long treatment cycle, a short drug release time, and a thin matrix that leads to insufficient penetration of skin, making it difficult to deeply treat fungal infections, and the fungal biofilm barrier affects the efficacy of the drug.

Method used

By optimizing the preparation process of miconazole nitrate, nanoscale miconazole nitrate cream was prepared, and allantoin eugenol amide ester penetration promoter was added, and the high-pressure homogenization method was used to improve the absorption rate and deep permeability of the drug.

Benefits of technology

It significantly improves the efficacy of miconazole nitrate, shortens the treatment cycle, enhances the therapeutic effect on deep fungal infections, and prevents the cream from turning yellow and deteriorating through antioxidant functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120131535A_ABST
    Figure CN120131535A_ABST
Patent Text Reader

Abstract

The invention provides miconazole nitrate emulsifiable paste and a preparation process, and belongs to the technical field of external medicines, and the miconazole nitrate emulsifiable paste is characterized by comprising the following components in parts by mass: 1.8-2.0 wt% of miconazole nitrate, 0.3-2.0 wt% of an allantoin eugenol amide ester penetration enhancer, 3-5 wt% of medium-chain triglyceride, 5-10 wt% of glycerin monostearate, 8-15 wt% of white vaseline, 6-12 wt% of glycerol and the balance of water. The cleaning agent is prepared from, by weight, 0.01%-0.10% of bis (hydroxymethyl) imidazolidinyl urea, 6%-12% of octadecanol, 1%-3% of triethanolamine and the balance purified water. The preparation process comprises the steps of preparation of cream, homogenization of miconazole nitrate emulsion and preparation of the miconazole nitrate cream. According to the invention, the nanoscale miconazole nitrate cream product with uniform and fine texture is prepared from the aspects of drug particle size optimization and homogenization; the added allantoin eugenol amide ester penetration enhancer is safe and non-irritant, and when the allantoin eugenol amide ester penetration enhancer and miconazole nitrate are used together, penetration of the ointment is promoted, and skin recovery is accelerated; meanwhile, the problems of yellowing, deterioration and the like of the cream can be effectively prevented.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of topical drugs, and particularly relates to miconazole nitrate cream and its preparation process. Background Art

[0002] Tinea is a common skin disease in dermatology, including tinea corporis, tinea cruris, tinea manus and pedis, etc. It is caused by local fungal infection, and the fungus parasitizes and multiplies deep in the skin. The fungus can survive for a long time at -20°C. On hair, nails, dandruff, etc. detached from the living body, it can remain active for more than one year. Even at a high temperature of 120°C, it can continue to survive for 10 minutes. When the body's resistance decreases and external factors are adverse, it may cause systemic or local fungal infections.

[0003] Miconazole nitrate is a synthetic 1-phenethylimidazole derivative and belongs to the imidazole broad-spectrum antifungal drugs. It is a commonly used drug for treating tinea corporis, with the characteristics of safety, high efficiency, multiple effects and unique multi-directional inhibition of fungi. It is suitable for treating systemic and disseminated infections caused by fungi such as Cryptococcus neoformans and Candida albicans. Miconazole Nitrate, molecular formula C 19 H 14 Cl 4 N 2 O·HNO 3 , which is the nitrate form of miconazole. Its mechanism of action is to inhibit the activity of the fungal cytochrome P450 enzyme system and interfere with the synthesis of the fungal cell membrane, thereby preventing the growth and reproduction of fungi. Research reports show that miconazole nitrate can inhibit most clinically isolated fungi at a concentration below 4 μg / mL, and the overall effective rate is close to 80%. In particular, it can achieve a high inhibition rate against Cryptococcus neoformans, Candida, Blastomyces dermatitidis and Histoplasma capsulatum.

[0004] Due to the easy recurrence of fungal infections, currently, miconazole nitrate cream usually has a long treatment cycle (2 - 5 weeks) for fungal infection diseases such as tinea, and it is still necessary to continue taking the medicine for 10 days to prevent recurrence. On the other hand, the drug release and sustained action time of miconazole nitrate cream are relatively short and the matrix is relatively thin, and its skin permeability is insufficient, especially for parts with a thick skin cutin layer such as the soles of the feet and palms, resulting in difficulty for the drug to penetrate the skin to reach the deep infection site and play a role, thus affecting its treatment effect on deep fungal infections. In addition, when a fungal biofilm is formed at the lesion site, the antibacterial effect of miconazole nitrate is greatly weakened, and it is urgent to find new methods to break through the fungal biofilm barrier.

[0005] Therefore, improving the miconazole nitrate process to obtain a miconazole nitrate product with a more uniform particle size and smaller size can not only improve its drug efficacy, but also deeply treat fungal infections, and has a broad market prospect. Summary of the Invention

[0006] To solve the above problems, this section aims to provide miconazole nitrate cream and its preparation process to improve the drug absorption rate and thus enhance the drug efficacy.

[0007] The present invention provides miconazole nitrate cream, which includes the following components by mass:

[0008] 1.8wt% - 2.0wt% miconazole nitrate, 0.3wt% - 2.0wt% allantoin eugenol amide ester penetration enhancer, 3wt% - 5wt% medium-chain triglyceride, 5wt% - 10wt% glyceryl monostearate, 8wt% - 15wt% white petrolatum, 6wt% - 12wt% glycerol, 0.01wt% - 0.10wt% bis(hydroxymethyl) imidazolidinyl urea, 6wt% - 12wt% stearyl alcohol, 1wt% - 3wt% triethanolamine, and the balance is purified water; the structural formula of the allantoin eugenol amide ester penetration enhancer is as follows:

[0009]

[0010] As a preferred technical solution of the present invention, the miconazole nitrate is prepared by the following steps:

[0011] a. 2-Amino-2',4'-dichlorobenzophenone reacts with glyoxal, formaldehyde and ammonium acetate in a 1,4-dioxane medium to obtain intermediate 1;

[0012] b. Intermediate 1 undergoes a reductive etherification reaction with 2,4-dichlorobenzyl alcohol and chlorodimethylsilane in an acetic acid-acetonitrile medium to obtain miconazole particles;

[0013] c. After the miconazole particles are subjected to a sanding process, nitric acid is added until the pH is 1 - 1.5 to obtain miconazole nitrate.

[0014] As a preferred technical solution of the present invention, in process a, the molar ratio of 2-amino-2',4'-dichlorobenzophenone to glyoxal, formaldehyde and ammonium acetate is (1 - 1.2):1:1:1; in process b, the molar ratio of intermediate 1 to 2,4-dichlorobenzyl alcohol and chlorodimethylsilane is 1:(1.1 - 1.2):(1.2 - 1.4), and the volume ratio of acetic acid to 1,4-dioxane is (0.5 - 1):10.

[0015] As a preferred technical solution of the present invention, the sanding process conditions are as follows: the miconazole-propylene glycol slurry with a solid content of 30% - 50% is sanded in a sand mill with grinding media for 3 - 6 h; the grinding media are mixed zirconia beads with a diameter of Φ1.8 - 2.0 mm, Φ1.0 - 1.2 mm and Φ0.4 - 0.6 mm in a mass ratio of (1 - 4):(3 - 5):(2 - 5); the mass ratio of the grinding media to the slurry is (4 - 6):1.

[0016] As a preferred technical solution of the present invention, the synthesis process of the allantoin eugenol amide ester penetration enhancer is as follows: allantoin and eugenol are reacted in a water bath at 60-80 °C for 3-6 h under an acidic catalyst, and the molar ratio of allantoin, eugenol to the acidic catalyst is 1:(1.1-1.3):(0.2-0.5); the acidic catalyst is one of phosphoric acid, sulfuric acid and p-toluenesulfonic acid.

[0017] The allantoin eugenol amide ester penetration enhancer of the present invention is a novel, highly efficient, safe and non-toxic transdermal absorption enhancer, which can significantly promote the transdermal penetration of drugs, thereby improving the utilization rate and efficacy of drugs in the body. It can also form hydrogen bonds or van der Waals forces with drug molecules, making the drug molecules more stable and less likely to be oxidized or degraded, thereby prolonging the shelf life of the drug, and having safety and good compatibility.

[0018] The present invention also provides a preparation process of the above-mentioned miconazole nitrate cream, which includes the following steps: preparing an oil phase matrix and an aqueous phase matrix respectively, and then mixing them to obtain a cream; subjecting nano miconazole, the allantoin eugenol amide ester penetration enhancer and a solvent to high-pressure homogenization to obtain a homogenized miconazole nitrate emulsion; mixing miconazole nitrate and the allantoin amide ester penetration enhancer in medium-chain triglycerides after high-pressure homogenization process with the cream to obtain a uniformly dispersed paste, and then performing degassing, cooling, perfusion and packaging to obtain miconazole nitrate cream;

[0019] The oil phase matrix includes white petrolatum, glyceryl monostearate, and stearyl alcohol, and the aqueous phase matrix includes purified water, imidazolidinyl urea, glycerol, and triethanolamine.

[0020] As a preferred technical solution of the present invention, the preparation process of the cream is specifically as follows:

[0021] S1. Add white petrolatum, glyceryl monostearate, and stearyl alcohol to container A, heat and stir at a temperature of 75-80 °C and a stirring speed of 400-600 rpm until completely melted to obtain an oil phase matrix; add purified water, imidazolidinyl urea, glycerol, and triethanolamine to container B, heat the system to 60-65 °C, and stir to obtain an aqueous phase matrix;

[0022] S2. Slowly add the oil phase matrix to the aqueous phase matrix while it is hot, and heat and stir at 70-75 °C and a stirring condition of 1000-1500 rpm until a milky white cream is formed.

[0023] As a preferred technical solution of the present invention, the high-pressure homogenization process is specifically as follows: Miconazole nitrate is mixed with allantoin eugenol amide ester penetrant and medium-chain triglycerides in pure water, and ultrasonic dispersion is carried out at a power of 150-200W to obtain a coarse dispersion system with a solid content of 10%-25%; The coarse dispersion system is homogenized and circulated 3-8 times in a high-pressure homogenizer at a homogenization pressure of 800-1000 bar to obtain miconazole nitrate emulsion.

[0024] The high-pressure homogenization method is to force a coarse dispersion system containing drugs through a narrow gap under high pressure, generating high shear force and cavitation effect, so that the drug particles are broken into nanoscale sizes. Excessive pressure may damage the chemical structure or crystal form of miconazole, thus affecting the drug efficacy. Relying on the action of a high-pressure homogenizer, lipid materials are dissolved and added to the aqueous phase containing surfactants, and after forming a primary emulsion, it is then processed by a high-pressure homogenizer to form a liposome solution with small particle size and uniform distribution.

[0025] The beneficial effects of the present invention:

[0026] The added allantoin eugenol amide ester penetrant of the present invention is safe and non-irritating. When used together with miconazole nitrate, it not only promotes the penetration of the ointment and accelerates the recovery of the skin, but also has a certain antioxidant function and can effectively prevent problems such as yellowing and deterioration of the cream.

[0027] The present invention is optimized from the perspectives of drug particle size optimization and homogenization, and a nano-scale miconazole nitrate cream product with uniform and delicate texture is prepared; moreover, the allantoin eugenol amide ester penetrant of the present invention is safe and non-irritating. When used together with miconazole nitrate, it not only promotes the penetration of the ointment and accelerates the recovery of the skin, but also has a certain antioxidant function and can effectively prevent problems such as yellowing and deterioration of the cream. Description of the drawings

[0028] Figure 1 It is the reaction equation for the preparation of miconazole nitrate in the present invention.

[0029] Figure 2 It is the 1H NMR spectrum of the allantoin eugenol amide ester penetrant of the present invention.

[0030] Figure 3 It is the cumulative penetration curve of miconazole nitrate cream in each example and comparative example. Detailed implementation manners

[0031] To make the above objects, features, and advantages of the present invention more apparent and understandable, the following specifically describes the specific embodiments of the present invention in detail. Many specific details are set forth in the following description to facilitate a full understanding of the present invention. However, the present invention can also be implemented in other ways different from those described herein. Those skilled in the art can make similar generalizations without departing from the connotation of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed below.

[0032] Unless otherwise specified, the percentages involved in the present invention are weight percentages.

[0033] Unless otherwise specified, the drugs used in the present invention are all commercially available.

[0034] CLBN-60 high-efficiency rod pin horizontal nano sand mill, power 45 kW, Chiller (Shanghai) Machinery Technology Co., Ltd.; 0.2 - 2 mm. AH-PILOT 16 high-pressure homogenizer, the maximum homogenization pressure can reach 1000 bar, no residue, the processing flow rate is 50 - 60 L / h, the minimum sample processing volume is 50 mL, power 5.5 kW, Antos Nano Technology (Suzhou) Co., Ltd.

[0035] Toughened yttrium zirconia beads (94.6% ZrO 2 +2.2% Y 2 O 3 , Φ0.4 - 0.6 mm, Φ1.0 - 1.2 mm, Φ1.8 - 2.0 mm), Chiller (Shanghai) Machinery Technology Co., Ltd., specific parameters are shown in Table 1.

[0036] Table 1

[0037] Zircon bead specifications <![CDATA[True density g / cm 3 > <![CDATA[Bulk density / g / cm 3 > Mohs hardness / grade Flexural strength / MPa Φ0.4 - 0.6mm 6.00 3.85 9 900 Φ1.0 - 1.2mm 6.00 3.82 9 900 Φ1.8 - 2.0mm 6.00 3.79 9 900

[0038] In the following specific embodiments, the preparation steps of miconazole nitrate are as follows:

[0039] a. Load 0.12 mol of 2-amino-2',4'-dichlorophenylethanone, 10 mmol of glyoxal, 10 mmol of ammonium acetate, and acetic acid (2 mL, 35 mmol) into a glass tube with a volume of about 20 mL, a body length of 18 cm, and a neck length of 9 cm. Add 20 mL of 1,4-dioxane, mix well, degas by liquid nitrogen freezing, vacuum seal, and place in an oven at 60 °C for 3 days after returning to room temperature. After the reaction, filter, wash the precipitate with ethanol (10 mL × 5), dichloromethane (10 mL × 5), and tetrahydrofuran (10 mL × 5), collect by filtration again, and dry in vacuum at 110 °C to obtain Intermediate 1, with a yield of 82.4%.

[0040] 1 H NMR (400HZ, CDCl 3):δ 7.86 - 7.84 (d, 1H, J = 7.15 Hz), 7.67 (t, 1H, J = 1.26 Hz), 7.54 (d, 1H, J = 1.76 Hz), 7.39 (dd, 1H, J = 6.97, 1.68 Hz), 7.33 (dd, 1H, J = 3.19, 1.31 Hz), 7.01 (dd, 1H.J = 3.25, 1.28 Hz), 5.86 (s, 2H).

[0041] b: Under argon protection, 02.5 mmol of intermediate 1 and 2.75 mmol of 2,4 - dichlorobenzyl alcohol were dissolved in 5 mL of acetonitrile, and 2.75 mmol of chlorodimethylsilane was added and mixed. The reaction mixture was stirred at room temperature for 15 h, and then 1 mL of NaHCO 3 aqueous solution was used to quench the reaction; washed with saturated brine, separated by liquid - liquid extraction, and dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (pentane / ethyl acetate = 8:1) to obtain miconazole particles with a yield of 74% and a purity of 99.7%. The synthetic scheme of miconazole nitrate is shown in Figure 1 .

[0042] 1 1H NMR: δ 7.70 (t, 1H, J = 1.48 Hz), 7.52 (d, 1H, J = 1.61 Hz), 7.44 (d, 2H, J = 1.16, 0.60 Hz), 7.44 - 7.42 (dd, 2H, J = 6.99, 0.50 Hz), 7.39 (dd, 1H, J = 6.79, 1.69 Hz), 7.34 - 7.31 (ddd, 2H, J = 7.81, 7.43, 6.62 Hz), 7.21 (dd, 1H, J = 3.37, 1.48 Hz), 7.07 (dd, 1H, J = 3.39, 1.37 Hz), 5.16 (td, 1H, J = 4.01, 0.75 Hz), 4.72 (s, 2H), 4.43 - 4.36 (ddd, 2H, J = 14.30, 10.59, 3.98 Hz).

[0043] c. Disperse miconazole microparticles in a 50% propylene glycol - aqueous solution for premixing to obtain a slurry with a solid content of 35%, and add it to the raw material barrel of the sand mill. Load a mixture of zirconia beads with diameters of Φ1.8 - 2.0 mm, Φ1.0 - 1.2 mm, and Φ0.4 - 0.6 mm in a mass ratio of 2:5:3 into the sand mill chamber, with a filling rate of 80%; turn on the reflux condensation device to control the temperature in the sand mill chamber not exceeding 20°C; set the rotation speed of the sand mill to 500 rpm and the linear velocity to 10 m / s. Grind in the sand mill with the grinding medium for 4.5 h; after the grinding is completed, obtain a fine slurry; add nitric acid to the fine slurry until the pH of the solution is ~1, and a large amount of white solid precipitates; after suction filtration and drying, obtain miconazole nitrate.

[0044] Use a Bettersize2000 intelligent laser particle size analyzer to detect miconazole microparticles, the miconazole fine slurry after sanding, and miconazole nitrate, and calculate the particle size distribution width (SPAN) value. Among them, SPAN = (D90 - D10) / D50. The results are shown in Table 2.

[0045] Table 2

[0046] Particle size parameter Miconazole microparticle Miconazole fine slurry after sanding Miconazole nitrate D50 / μm 158.4±19.2 8.9±1.4 10.4±3.5 SPAN 1.67 0.92 1.03

[0047] From Table 2, the particle size of the miconazole slurry after sanding decreased by one order of magnitude, and the distribution became more uniform; the particle size of miconazole nitrate increased slightly compared with that of the miconazole fine slurry, which was caused by the agglomeration or combination of some particles during the process of forming a solid after adding nitric acid.

[0048] In the following specific embodiments, the synthesis steps of the allantoin eugenol amide penetrant are as follows: Dissolve 11 mmol of eugenol and 1 mmol of p - toluenesulfonic acid in tetrahydrofuran, and then add 10 mmol of allantoin and mix; place the reaction mixture in a 65°C water bath and stir for 5 h. After the reaction is completed, wait until it cools to room temperature, recrystallize the precipitate with ethyl acetate, and obtain the product after evaporating the solvent, with a yield of 81.4%. The NMR results are shown in Figure 2 .

[0049] Examples 1 - 4

[0050] Obtain miconazole nitrate cream according to the following preparation process:

[0051] Preparation of the cream: Add white petrolatum, glyceryl monostearate, and stearyl alcohol to container A, heat to 75°C and stir at a stirring speed of 500 rpm, and pass through a 150 - mesh sieve to obtain the oil - phase matrix; add purified water, imidazolidinyl urea, glycerol, and triethanolamine to container B, heat the system to 60°C, and stir at 500 rpm to obtain the water - phase matrix; slowly add the oil - phase matrix to the water - phase matrix while it is hot and mix, and heat and stir at 70°C and 1500 rpm until a milky white cream is formed.

[0052] Preparation of Miconazole Nitrate Cream: Miconazole nitrate is mixed with allantoin acylurea penetration enhancer and medium-chain triglycerides in pure water, and ultrasonic emulsification is carried out at 150W for 10 minutes to obtain a coarse dispersion system with a solid content of 18.8%; after 5 cycles of high-pressure homogenization process under a pressure of 1000 bar, a homogenized miconazole nitrate emulsion is obtained; the homogenized miconazole nitrate emulsion is heated to 40 - 50 °C, and then added to the cream while it is hot. The mixed system is continuously stirred at 60 °C and 2500 rpm for 30 minutes to obtain a uniformly dispersed paste, degassed, cooled, and then filled and packaged.

[0053] The formulations of the miconazole nitrate creams in Examples 1 - 4 are shown in Table 3.

[0054] Table 3

[0055]

[0056] Example 5

[0057] The difference between this example and Example 1 is that the mass ratio of three kinds of zirconia beads with diameters of Φ1.8 - 2.0 mm, Φ1.0 - 1.2 mm, and Φ0.4 - 0.6 mm is changed to 1:4:5.

[0058] Examples 6 - 7

[0059] The difference between this example and Example 1 is that the number of cycles of high-pressure homogenization is 3 times and 8 times.

[0060] Comparative Example 1

[0061] The difference from Example 1 is that the sanding process is omitted in step (1).

[0062] Comparative Example 2

[0063] The difference from Example 1 is that the high-pressure homogenization process is omitted in step (3).

[0064] Comparative Example 3

[0065] The difference from Example 1 is that step (2) is omitted, that is, the synthesized penetration enhancer is not added in step (3).

[0066] Comparative Example 4

[0067] The difference from Example 1 is that the penetration enhancer is a 1:1 mass ratio mixture of allantoin and eugenol.

[0068] 1. Conduct skin safety tests on the miconazole nitrate creams in the above examples and comparative examples.

[0069] The test method is the human skin patch test: Dilute the products of each application example and place them in a patch tester, with a dose of 20 - 30 mg; then apply the patch tester with the test substance on the flexor side of the forearm of the subject using a non-irritating tape, and gently press with the palm to make it evenly adhere to the skin for 48 h. Observe the skin reaction 30 min after removing the patch tester with the test substance, after the indentation disappears; 24 h later, apply the patch tester with the test substance on the back or the flexor side of the forearm of the subject again using a non-irritating tape, and gently press with the palm to make it evenly adhere to the skin for 48 h. Observe the skin reaction 30 min after removing the patch tester with the test substance, after the indentation disappears. The grading standard for skin reactions in the skin closed patch test is shown in Table 4, and the patch test results are shown in Table 5.

[0070] Table 4

[0071]

[0072] Table 5

[0073]

[0074] From Table 5, no skin adverse reactions occurred in all miconazole nitrate cream products. It is preliminarily concluded that the use safety of the miconazole nitrate cream with the allantoin eugenol amide ester penetration enhancer involved in the present invention is highly guaranteed and is not expected to cause skin adverse reactions.

[0075] 2. Inspection of basic technical indicators:

[0076] Physical properties: This product should be a white, delicate and shiny cream with a suitable pH.

[0077] Drug identification: Take this product, dissolve and dilute it with a methanol-hydrochloric acid solution (0.1 mol / L) with a volume ratio of 9:1 to prepare a solution containing 0.4 mg of miconazole nitrate per 1 mL, and determine it according to the ultraviolet-visible spectrophotometry (General Principles 0401 of the Pharmacopoeia of the People's Republic of China: 2020 Edition) in the wavelength range of 240 - 300 nm. It has maximum absorption at the wavelengths of 264 nm, 272 nm and 280 nm, and the absorbances are approximately 0.40, 0.50 and 0.44 respectively.

[0078] Assay: Determine it according to the high performance liquid chromatography method (General Principles 0512 of the Pharmacopoeia of the People's Republic of China: 2020 Edition). Chromatographic conditions: Inersil C18 column (4.6 mm × 250 mm, 5 μm); a mixture of 0.5% ammonium acetate solution - acetonitrile and methanol (1:1) (v:v = 15:85) is used as the mobile phase; the detection wavelength is 238 nm, the flow rate is 1.0 mL / min, the column temperature is 30 °C, and the injection volume is 20 μL.

[0079] Accurately weigh the reference substance of miconazole nitrate (purity 99%, Wuhan Nengmaike Industrial Co., Ltd.), dissolve it with chloroform-methanol (1:1) to make a solution with a concentration of 8.0 mg / mL; then dilute it with chloroform-methanol (1:1) to concentration (C) gradients of 0.5, 1.0, 2.0, 4.0, and 8.0 mg / mL, and measure the peak area (S) under the following chromatographic conditions:

[0080] Use octadecylsilane chemically bonded silica gel as the filler; use methanol-acetonitrile-11.5% ammonium acetate solution (40:40:20) as the mobile phase; the detection wavelength is 230 nm. Take 10 μL of the system suitability test solution and inject it into the liquid chromatograph; take 10 μL of the reference solution and inject it into the liquid chromatograph, adjust the detection sensitivity to make the peak height of the main component chromatographic peak about 25% of the full scale; then accurately measure 10 μL of the test solution and the reference solution respectively, inject them into the liquid chromatograph, and record the chromatogram until 2 times the retention time of the main component peak. Make a regression calculation with S as the vertical coordinate and C as the horizontal coordinate. The regression equation is: S = 102.1 + 0.5718, R 2 = 99.98%.

[0081] Accurately weigh 2.5 g of miconazole nitrate ointment, place it in a 50 mL volumetric flask, dissolve it with chloroform-methanol (1:1), and make up to the mark. Obtain the content of miconazole nitrate according to the peak area and the above regression equation.

[0082] Particle size: Use the Bettersize2000 intelligent laser particle size analyzer to detect the particle size and SPAN value of the cream.

[0083] Cream stability: Package the miconazole nitrate cream and conduct an accelerated stability test. Take three parallel samples in packages and place them in an incubator at 55 °C for 3 months. After taking them out, measure the content of miconazole nitrate and observe the properties of the cream.

[0084] Summarize the above test results in Table 6.

[0085] Table 6

[0086]

[0087] 3. In vitro percutaneous permeability test:

[0088] Adopt the transdermal diffusion test method. The test device is a vertical Franz diffusion cell, YB-P6 intelligent transdermal test instrument (Shanghai Jingsheng Scientific Instruments Co., Ltd.), and its effective transdermal diffusion area is 3.4 cm × 3.2 cm = 10.88 cm 2 , and the volume of the receiving chamber is 17 mL (vertical). Select the back skin of Bama mini-pig similar to the human skin structure, which can more truly simulate the transdermal characteristics of human skin.

[0089] Remove the hair from the pigskin using an electric scissors, peel off the skin of the required part, remove the subcutaneous fat and fascia tissue, rinse it thoroughly with physiological saline, soak the treated skin in physiological saline for about 30 minutes, take it out and dry it with filter paper for standby.

[0090] Select 60% polyethylene glycol 400 - 40% physiological saline as the receiving solution for the in vitro percutaneous penetration test. Fix the pigskin between the two half-cells of the diffusion cell, and add 17 mL of the receiving solution to the receiving cell. After pre-equilibrating the diffusion cell in a water bath at (32 ± 1)°C for 1 h, evenly apply 0.5 g of miconazole nitrate ointment on the surface of the pigskin. At 0.5, 1, 2, 4, 6, 8, and 24 h, respectively, draw 2 mL of the absorption solution from the receiving chamber, filter it through a 0.22 μm microfiltration membrane, and inject it into a high-performance liquid chromatograph (EClassical 3200 high-performance liquid chromatograph, Dalian Elite Analytical Instruments Co., Ltd.) for analysis and determination of the drug concentration. At the same time, add an equal amount of blank receiving solution to the receptor cell.

[0091] The cumulative permeation amount (μg / cm 2 ) is calculated by the formula:

[0092]

[0093] In the formula, C n is the drug concentration measured at the nth sampling point; V is the volume of the receiving chamber; C i is the drug concentration measured at the ith sampling point; V is the sampling volume; A is the permeation area (cm 2 ).

[0094] The cumulative permeation curve of the above miconazole nitrate cream sample is shown in Figure 3 .

[0095] Combined with Table 2, Table 6 and Figure 3 , in Comparative Example 1 or Comparative Example 2, due to the non-optimization of the particle size of the miconazole raw material or the lack of high-pressure homogenization operation for the miconazole nitrate emulsion, the particle size of the final cream product differed by several times, which was not conducive to the absorption of the product on the skin surface; among them, the high-pressure homogenization process had a greater impact on the particle size and uniformity of the cream product.

[0096] The comparison between Comparative Examples 3, 4, 5 and Example 1 shows that the allantoin eugenol amide ester penetration enhancer provided by the present invention has a higher transdermal efficiency than the physical mixture of allantoin and eugenol: allantoin eugenol amide ester forms a stable structure through chemical bonding and is more suitable for use in complex environments, while the mixed penetration enhancer relies on physical mixing. And as can be seen from Table 5, the allantoin eugenol amide ester penetration enhancer has a penetration enhancing effect and does not cause damage or irritation to the skin.

[0097] In summary, in the preparation process of the miconazole nitrate cream provided by the present invention, optimization is carried out from three aspects: improving the purity of raw materials, refining the particle size of raw materials by sand grinding, and homogenizing the cream, and a nano-level miconazole nitrate cream product with uniform and delicate texture is prepared; and by adding allantoin eugenol amide as a penetration enhancer, the solubility of the drug in the skin is further increased, and the skin penetration rate of the miconazole nitrate drug is improved.

[0098] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified or equivalently replaced without departing from the spirit and scope of the technical solutions of the present invention, and they should all be covered within the scope of the claims of the present invention.

Claims

1. A miconazole nitrate cream, characterized in that, The invention comprises the following components by weight: 1.8wt% to 2.0wt% of miconazole nitrate, 0.3wt% to 2.0wt% of allantoin eugenol amide ester penetration enhancer, 3wt% to 5wt% of medium chain triglycerides, 5wt% to 10wt% of glyceryl monostearate, 8wt% to 15wt% of white vaseline, 6wt% to 12wt% of glycerol, 0.01wt% to 0.10wt% of bis(hydroxymethyl)imidazolidinyl urea, 6wt% to 12wt% of octadecyl alcohol, 1wt% to 3wt% of triethanolamine, and the balance of purified water; the structural formula of the allantoin eugenol amide ester penetration enhancer is as follows:

2. miconazole nitrate cream as claimed in claim 1, wherein the miconazole nitrate is prepared by the following steps: a. 2-amino-2',4'-dichloroacetophenone reacts with glyoxal, formaldehyde and ammonium acetate in 1,4-dioxane medium to obtain intermediate 1; b. The intermediate 1 is subjected to a reduction etherification reaction with 2,4-dichlorobenzyl alcohol and chlorodimethylsilane in an acetic acid-acetonitrile medium to obtain miconazole microparticles; c. After the miconazole microparticles are sand-milled, nitric acid is added to a pH value of 1 to 1.5 to obtain miconazole nitrate.

3. miconazole nitrate cream as claimed in claim 2, characterized in that, In process a, the molar ratio of the 2-amino-2',4'-dichloroacetophenone to glyoxal, formaldehyde and ammonium acetate is (1-1.2):1:1:1; in process b, the molar ratio of the intermediate 1 to 2,4-dichlorobenzyl alcohol and chlorodimethylsilane is 1:(1.1-1.2):(1.2-1.4), and the volume ratio of acetic acid to 1,4-dioxane is (0.5-1):

10.

4. miconazole nitrate cream as claimed in claim 2, characterized in that, The sand milling process conditions are as follows: a miconazole-propylene glycol slurry with a solid content of 30% to 50% is sand milled in a sand mill with a grinding medium for 3 to 6 hours; the grinding medium is a mixed zirconium oxide bead with a mass ratio of (1 to 4): (3 to 5): (2 to 5) of Φ1.8 to 2.0 mm, Φ1.0 to 1.2 mm and Φ0.4 to 0.6 mm; the mass ratio of the grinding medium to the slurry is (4 to 6):

1.

5. miconazole nitrate cream as claimed in claim 1, characterized in that, The synthesis process of the allantoin eugenol amide ester penetration enhancer is as follows: allantoin and eugenol are reacted in a water bath at 60-80° C. under an acidic catalyst for 3-6 hours, and the molar ratio of allantoin, eugenol and the acidic catalyst is 1:(1.1-1.3):(0.2-0.5); the acidic catalyst is one of phosphoric acid, sulfuric acid and p-toluenesulfonic acid.

6. A preparation process of miconazole nitrate cream, characterized in that: The method comprises the following steps: preparing an oil phase matrix and an aqueous phase matrix respectively, and then mixing them to obtain an ointment; homogenizing nano-miconazole nitrate, an allantoin eugenol amide ester permeation promoter, and a solvent under high pressure to obtain a homogenized miconazole nitrate emulsion; mixing miconazole nitrate and an allantoin amide ester permeation promoter with the ointment after a high pressure homogenization process in medium chain triglycerides to obtain a uniformly dispersed paste, and performing degassing, cooling, and perfusion packaging to obtain a miconazole nitrate cream; The oil phase matrix includes white vaseline, glyceryl monostearate and octadecyl alcohol, and the water phase matrix includes purified water, bis(hydroxymethyl)imidazolidinyl urea, glycerol and triethanolamine.

7. The preparation process of miconazole nitrate cream as claimed in claim 6, characterized in that, The preparation process of the cream is specifically as follows: S1. Add white vaseline, glyceryl monostearate, and octadecyl alcohol to container A, heat and stir at 75-80° C. and 400-600 rpm until completely melted to obtain an oil phase matrix; add purified water, bis(hydroxymethyl)imidazolidinyl urea, glycerol, and triethanolamine to container B, heat the system to 60-65° C., and stir at 400-600 rpm to obtain an aqueous phase matrix; S2. Slowly add the oil phase matrix into the water phase matrix while it is hot and mix, and heat and stir at 70-75° C. and 1000-1500 rpm to form a milky white cream.

8. The preparation process of miconazole nitrate cream as claimed in claim 6, characterized in that, The high-pressure homogenization process is specifically as follows: miconazole nitrate, allantoin eugenol amide ester penetration enhancer and medium-chain triglyceride are mixed in pure water, and ultrasonically dispersed at a power of 150 to 200 W to obtain a coarse dispersion system with a solid content of 10% to 25%; and the coarse dispersion system is homogenized in a high-pressure homogenizer at a homogenization pressure of 800 to 1000 bar for 3 to 8 times to obtain a miconazole nitrate emulsion.

Citation Information

Patent Citations

  • Method for producing miconazole nitrate on industrialized basis

    CN101863832A

  • Preparation method of miconazole nitrate

    CN104610154A

  • Miconazole nitrate emulsifiable paste and preparation method thereof

    CN108042483A

  • Miconazole nitrate cream and preparation method thereof

    CN115227641A

  • Ketoconazole nanocrystal suspension as well as preparation method and application thereof

    CN116919897A